Abstract:Tuberculosis (TB) continues to be a global health crisis, necessitating urgent interventions to address drug resistance and improve treatment efficacy. In this study, we validate lumazine synthase (RibH), a vital enzyme in the riboflavin biosynthetic pathway, as a potential drug target against Mycobacterium tuberculosis (M. tb) using a CRISPRi-based conditional gene knockdown strategy. We employ a high-throughput molecular docking approach to screen ~ 600,000 compounds targeting RibH. Through in vitro screening of 55 shortlisted compounds, we discover 3 compounds that exhibit potent antimycobacterial activity. These compounds also reduce intracellular burden of M. tb during macrophage infection and prevent the resuscitation of the nutrient-starved persister bacteria. Moreover, these three compounds enhance the bactericidal effect of first-line anti-TB drugs, isoniazid and rifampicin. Corroborating with the in silico predicted high docking scores along with favourable ADME and toxicity profiles, all three compounds demonstrate binding affinity towards purified lumazine synthase enzyme in vitro, in addition these compounds exhibit riboflavin displacement in an in vitro assay with purified lumazine synthase indicative of specificity of these compounds to the active site. Further, treatment of M. tb with these compounds indicate reduced production of flavin adenine dinucleotide (FAD), the ultimate end product of the riboflavin biosynthetic pathway suggesting the action of these drugs on riboflavin biosynthesis. These compounds also show acceptable safety profile in mammalian cells, with a high selective index. Hence, our study validates RibH as an important drug target against M. tb and identifies potent antimycobacterial agents.

What problem does this paper attempt to address?

This paper attempts to address several key issues in the treatment of tuberculosis (TB): 1. **Drug Resistance**: One of the main challenges faced by current anti-tuberculosis drugs is the increase in drug resistance. *Mycobacterium tuberculosis* (M. tb) easily develops resistance mutations to existing drugs, making treatment more difficult. 2. **Poor Treatment Outcomes**: The existing standard treatment regimen requires patients to take multiple drugs for a long period, usually lasting 6 to 9 months. Prolonged treatment not only increases the risk of patient non-compliance but may also lead to treatment failure and further development of drug resistance. 3. **Finding New Drug Targets**: To overcome the above issues, researchers have been searching for new drug targets, especially those that play important roles in *Mycobacterium tuberculosis* and have not been fully exploited. This paper focuses on a key enzyme in the riboflavin biosynthesis pathway—**riboflavin synthase (RibH, also known as lumazine synthase)**. 4. **Enhancing the Efficacy of Existing Drugs**: Researchers hope to discover new compounds that not only have antibacterial effects on their own but can also be used in combination with existing first-line anti-tuberculosis drugs (such as isoniazid and rifampicin) to enhance their bactericidal effects, shorten treatment duration, and reduce side effects. Specifically, this paper validates the effectiveness of riboflavin synthase (RibH) as a potential drug target through the following steps: - **Gene Knockdown Experiment**: Using CRISPRi technology to conditionally knock down the riboflavin synthase gene (*ribH*) and observe its impact on the growth of *Mycobacterium tuberculosis*. - **High-Throughput Molecular Docking**: Screening approximately 600,000 compounds to identify potential inhibitors that can bind to riboflavin synthase. - **In Vitro Screening**: Further testing the antibacterial activity of 55 initially screened compounds, ultimately identifying 3 compounds that exhibit significant antibacterial effects. - **Mechanism Validation**: Using various experimental methods (such as microscale thermophoresis, riboflavin displacement assay, FAD level measurement, etc.) to confirm that these compounds indeed exert their effects by inhibiting riboflavin synthase. - **Synergistic Effect**: Evaluating the synergistic effect of these compounds when used in combination with existing anti-tuberculosis drugs (such as isoniazid and rifampicin), finding that they can significantly enhance the bactericidal effects of existing drugs. - **Cytotoxicity Assessment**: Testing the safety of these compounds in mammalian cells, showing that they have a high selectivity index, indicating low toxicity to human cells. In summary, this paper aims to validate riboflavin synthase (RibH) as a new target for anti-tuberculosis drugs and has discovered some promising antibacterial compounds that can not only exert antibacterial effects on their own but also enhance the efficacy of existing drugs when used in combination.

Discovery of potent antimycobacterial agents targeting lumazine synthase (RibH) of Mycobacterium tuberculosis

Integrated virtual screening and MD simulation study to discover potential inhibitors of mycobacterial electron transfer flavoprotein oxidoreductase

Identification of potent indolizine derivatives against Mycobacterial tuberculosis: In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies

In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies of substituted 1,2,4-oxadiazole analogues against Mycobacterium tuberculosis

Approaches for targeting the mycobactin biosynthesis pathway for novel anti-tubercular drug discovery: where we stand

New Synergistic Benzoquinone Scaffolds as Inhibitors of Mycobacterial Cytochrome bc1 Complex to Treat Multi-Drug Resistant Tuberculosis

Discovery of small-molecule inhibitors targeting the ribosomal peptidyl transferase center (PTC) of M. tuberculosis

Identification and optimization of pyridine carboxamide-based scaffold as a drug lead for Mycobacterium tuberculosis

Identification of antituberculosis agents that target ribosomal protein interactions using a yeast two-hybrid system

Revitalizing antimicrobial strategies: paromomycin and dicoumarol repurposed as potent inhibitors of M.tb's replication machinery via targeting the vital protein DnaN

Multitarget Drug Discovery for Tuberculosis and Other Infectious Diseases

Phenotypic‐based Discovery and Exploration of a Resorufin Scaffold with Activity against Mycobacterium Tuberculosis

Cheminformatics-enhanced discovery of therapeutic agents targeting isocitrate lyase in Mycobacterium tuberculosis infections

Exploration of potential inhibitors for tuberculosis via structure‐based drug design, molecular docking, and molecular dynamics simulation studies

Structure based virtual screening and discovery of novel inhibitors against FabD protein of Mycobacterium tuberculosis

Computational analysis of RNA methyltransferase Rv3366 as a potential drug target for combating drug-resistant Mycobacterium tuberculosis

Genome mining of Mycobacterium tuberculosis: targeting SufD as a novel drug candidate through in silico characterization and inhibitor screening

An Extensive Computational Investigation of Mycobacterium tuberculosis Pantothenate Synthetase Inhibitors from Diverse‐Lib Compounds Library

Computational screening of natural MtbDXR inhibitors for novel anti-tuberculosis compound discovery

Discovery and evaluation of new compounds targeting ribosomal protein S1 in antibiotic-resistant Mycobacterium Tuberculosis.

Elucidation of marine fungi derived anthraquinones as mycobacterial mycolic acid synthesis inhibitors: an in silico approach